those in whom there was a confidant expectation that they could be rendered cancer free, has provided cohorts of patients staged T1N0M0 with survival rates of up to 80%–90%.

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

Published Online First 22 June 2012

doi:10.1136/thoraxjnl-2012-202006

REFERENCES


High sixes!

Andrew Bush,1 Ian Pavord2

The release of the 2012 impact factors have been really encouraging, with Thorax rising to 6.64, and the distance between ourselves and our nearest competitors, Chest and the European Respiratory Journal widening (but congratulations to the ERJ for leaping into third place). We remain the second ranked respiratory journal in the world. This has only happened because of the great manuscripts submitted to us by so many good groups, and the tireless work of the Deputy and Associate Editors, the Editorial Board, so many who have given generously of their time to review the papers, and all the editorial staff. Huge thanks to you all, and please keep it up. We are not complacent, however, and we want to use this encouragement to spur us to higher levels of performance and an even better impact factor in the last 3 years of our tenure.

And the second of the high sixes? Thorax’s answer to Tiger Woods (at least on the golf course), Ian Pavord, wishes it to be known that he has won the BTS Lipscomb Trophy for the 6th successive year. Always good to have someone conforming to the Ministerial stereotypes of Consultants!

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

Thorax 2012;67:761.
doi:10.1136/thoraxjnl-2012-202395

1National Heart and Lung Institute, Imperial College, London, UK; 2Glennfield Hospital, UK

Correspondence to Dr Andrew Bush, National Heart and Lung Institute, Imperial College, London, UK; a.bush@imperial.ac.uk

Editorial